Symbols / STTK Stock $7.74 +1.18% Shattuck Labs, Inc.

Healthcare • Biotechnology • United States • NMS
STTK (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Taylor H. Schreiber M.D., Ph.D.
Exch · Country NMS · United States
Market Cap 585.00M
Enterprise Value 478.26M
Income -48.81M
Sales 1.00M
FCF (ttm) -21.51M
Book/sh 1.30
Cash/sh 1.09
Employees 40
Insider 10d —
IPO Oct 09, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -16.21
PEG —
P/S 585.00
P/B 5.94
P/C —
EV/EBITDA -10.02
EV/Sales 478.26
Quick Ratio 11.07
Current Ratio 11.70
Debt/Eq 2.94
LT Debt/Eq —
EPS (ttm) -0.70
EPS next Y -0.48
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-04-30
Earnings (prior) 2026-03-05
ROA -35.31%
ROE -60.25%
ROIC —
Gross Margin -195.10%
Oper. Margin -51.43%
Profit Margin 0.00%
Shs Outstand 75.58M
Shs Float 47.57M
Insider Own 5.09%
Instit Own 63.74%
Short Float 1.85%
Short Ratio 2.39
Short Interest 1.34M
52W High 8.33
vs 52W High -7.08%
52W Low 0.71
vs 52W Low 987.08%
Beta 1.29
Impl. Vol. 3.28%
Rel Volume 0.43
Avg Volume 537.87K
Volume 230.97K
Target (mean) $12.00
Tgt Median $12.00
Tgt Low $7.00
Tgt High $18.00
# Analysts 6
Recom Buy
Prev Close $7.65
Price $7.74
Change 1.18%
About

Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program. The company was incorporated in 2016 and is headquartered in Austin, Texas.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$12.00
Mean price target
2. Current target
$7.74
Latest analyst target
3. DCF / Fair value
$-5.12
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$7.74
Low
$7.00
High
$18.00
Mean
$12.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-20 main HC Wainwright & Co. Buy → Buy $18
2026-03-13 main Citigroup Neutral → Neutral $7
2026-03-06 main Wedbush Outperform → Outperform $8
2026-01-28 init Piper Sandler — → Overweight $15
2026-01-06 main Citigroup Neutral → Neutral $4
2025-12-01 up HC Wainwright & Co. Neutral → Buy $6
2025-09-08 init Wedbush — → Outperform $4
2025-08-14 main Leerink Partners Outperform → Outperform $2
2025-08-14 reit Needham Hold → Hold —
2025-03-27 reit Needham Hold → Hold —
2025-03-27 reit HC Wainwright & Co. Neutral → Neutral —
2025-03-17 init Leerink Partners — → Outperform $4
2024-11-15 reit HC Wainwright & Co. — → Neutral —
2024-11-14 reit Needham — → Hold —
2024-10-02 down Citigroup Buy → Neutral $2
2024-10-02 down Needham Buy → Hold $8
2024-10-01 down HC Wainwright & Co. Buy → Neutral —
2024-08-27 reit HC Wainwright & Co. Buy → Buy $16
2024-08-15 main Citigroup Buy → Buy $8
2024-08-02 reit HC Wainwright & Co. Buy → Buy $16
News
RSS: Latest STTK news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-08-25 SCHREIBER TAYLOR M.D., PH.D. Chief Executive Officer — 25,610 $0.87 $22,222
2025-08-25 ORBIMED ADVISORS, L.L.C. Unknown — 6,306,127 $0.87 $5,471,826
2025-08-25 ASHIYA MONA Director — 6,306,127 $0.87 $5,471,826
2025-08-25 NEILL ANDREW R. Chief Financial Officer — 64,027 $0.87 $55,556
2025-08-25 SHUKLA ABHINAV A. PH.D. Chief Technology Officer — 5,122 $0.87 $4,444
2025-08-25 STOUT STEPHEN General Counsel — 12,805 $0.87 $11,111
2025-08-25 SIEGALL CLAY B Director — 128,054 $0.87 $111,112
2024-12-04 REDMILE GROUP, L.L.C. Director and Beneficial Owner of more than 10% of a Class of Security — 133,371 $1.25 $166,714
2024-12-04 REDMILE GROUP, L.L.C. Director and Beneficial Owner of more than 10% of a Class of Security — 133,371 $1.25 $166,714
2024-10-07 SCHREIBER TAYLOR M.D., PH.D. Chief Executive Officer — 36,500 $1.21 $44,220
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
1.00
-82.52%
5.72
+245.26%
1.66
+154.14%
0.65
Operating Revenue
1.00
-82.52%
5.72
+245.26%
1.66
+154.14%
0.65
Operating Expense
52.51
-39.15%
86.29
-7.83%
93.61
-9.97%
103.98
Research And Development
35.27
-47.52%
67.21
-9.55%
74.31
-10.36%
82.90
Selling General And Administration
17.23
-9.66%
19.08
-1.18%
19.30
-8.43%
21.08
General And Administrative Expense
17.23
-9.66%
19.08
-1.18%
19.30
-8.43%
21.08
Other Gand A
17.23
-9.66%
19.08
-1.18%
19.30
-8.43%
21.08
Total Expenses
52.51
-39.15%
86.29
-7.83%
93.61
-9.97%
103.98
Operating Income
-51.51
+36.07%
-80.57
+12.39%
-91.96
+11.01%
-103.33
Total Operating Income As Reported
-51.51
+36.07%
-80.57
+12.39%
-91.96
+11.01%
-103.33
EBITDA
-47.82
+37.68%
-76.74
+12.71%
-87.92
+12.31%
-100.26
Normalized EBITDA
-47.82
+37.68%
-76.74
+12.71%
-87.92
+12.31%
-100.26
Reconciled Depreciation
3.69
-3.68%
3.83
-5.27%
4.04
+31.53%
3.07
EBIT
-51.51
+36.07%
-80.57
+12.39%
-91.96
+11.01%
-103.33
Net Income
-48.81
+35.28%
-75.41
+13.62%
-87.30
+14.37%
-101.94
Pretax Income
-48.81
+35.28%
-75.41
+13.62%
-87.30
+14.37%
-101.94
Net Non Operating Interest Income Expense
2.70
-47.76%
5.17
+10.82%
4.67
+193.28%
1.59
Net Interest Income
2.70
-47.76%
5.17
+10.82%
4.67
+193.28%
1.59
Interest Income Non Operating
2.70
-47.76%
5.17
+10.82%
4.67
+193.28%
1.59
Interest Income
2.70
-47.76%
5.17
+10.82%
4.67
+193.28%
1.59
Other Income Expense
-0.00
+76.47%
-0.02
-70.00%
-0.01
+95.19%
-0.21
Other Non Operating Income Expenses
-0.00
+76.47%
-0.02
-70.00%
-0.01
+95.19%
-0.21
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-48.81
+35.28%
-75.41
+13.62%
-87.30
+14.37%
-101.94
Net Income From Continuing Operation Net Minority Interest
-48.81
+35.28%
-75.41
+13.62%
-87.30
+14.37%
-101.94
Net Income From Continuing And Discontinued Operation
-48.81
+35.28%
-75.41
+13.62%
-87.30
+14.37%
-101.94
Net Income Continuous Operations
-48.81
+35.28%
-75.41
+13.62%
-87.30
+14.37%
-101.94
Normalized Income
-48.81
+35.28%
-75.41
+13.62%
-87.30
+14.37%
-101.94
Net Income Common Stockholders
-48.81
+35.28%
-75.41
+13.62%
-87.30
+14.37%
-101.94
Diluted EPS
—
-1.49
+27.32%
-2.05
+14.94%
-2.41
Basic EPS
—
-1.49
+27.32%
-2.05
+14.94%
-2.41
Basic Average Shares
—
50.76
+19.15%
42.60
+0.52%
42.38
Diluted Average Shares
—
50.76
+19.15%
42.60
+0.52%
42.38
Diluted NI Availto Com Stockholders
-48.81
+35.28%
-75.41
+13.62%
-87.30
+14.37%
-101.94
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
91.03
-0.03%
91.05
-42.94%
159.56
-22.29%
205.32
Current Assets
82.47
+4.12%
79.22
-44.69%
143.22
-22.41%
184.58
Cash Cash Equivalents And Short Term Investments
78.06
+6.96%
72.99
-44.12%
130.62
-19.01%
161.28
Cash And Cash Equivalents
54.19
-5.57%
57.39
-54.32%
125.63
+165.15%
47.38
Other Short Term Investments
23.87
+53.03%
15.60
+212.06%
5.00
-95.61%
113.90
Prepaid Assets
—
—
—
—
Other Current Assets
4.41
-29.19%
6.23
-50.55%
12.60
-45.95%
23.30
Total Non Current Assets
8.55
-27.74%
11.83
-27.59%
16.34
-21.20%
20.74
Net PPE
6.11
-37.69%
9.81
-28.92%
13.80
-21.88%
17.67
Gross PPE
22.79
-1.05%
23.03
-1.21%
23.31
-0.30%
23.38
Accumulated Depreciation
-16.67
-26.16%
-13.22
-39.04%
-9.51
-66.51%
-5.71
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.64
+0.00%
0.64
+0.00%
0.64
+0.16%
0.64
Construction In Progress
—
0.00
-100.00%
0.10
-3.85%
0.10
Other Properties
15.27
-0.14%
15.29
-1.17%
15.47
-0.50%
15.55
Leases
6.88
-3.10%
7.10
+0.00%
7.10
+0.16%
7.09
Investments And Advances
1.00
0.00
—
—
Long Term Equity Investment
1.00
0.00
—
—
Other Non Current Assets
1.44
-28.93%
2.02
-20.39%
2.54
-17.24%
3.07
Total Liabilities Net Minority Interest
8.64
-24.40%
11.42
-23.12%
14.86
-49.06%
29.17
Current Liabilities
7.05
-20.92%
8.92
-22.14%
11.45
-54.12%
24.96
Payables And Accrued Expenses
3.21
-39.61%
5.32
-8.64%
5.82
-68.40%
18.43
Payables
2.10
-13.15%
2.42
+52.43%
1.59
-77.87%
7.17
Accounts Payable
2.10
-13.15%
2.42
+52.43%
1.59
-77.87%
7.17
Current Accrued Expenses
1.11
-61.69%
2.90
-31.52%
4.24
-62.38%
11.26
Pensionand Other Post Retirement Benefit Plans Current
2.77
+20.94%
2.29
-39.69%
3.79
-4.36%
3.97
Current Debt And Capital Lease Obligation
0.84
-7.00%
0.90
+13.07%
0.80
+13.55%
0.70
Current Capital Lease Obligation
0.84
-7.00%
0.90
+13.07%
0.80
+13.55%
0.70
Current Deferred Liabilities
—
—
—
—
Current Deferred Revenue
—
—
—
—
Other Current Liabilities
0.24
-42.44%
0.41
-60.61%
1.04
-44.36%
1.87
Total Non Current Liabilities Net Minority Interest
1.58
-36.79%
2.51
-26.42%
3.41
-18.94%
4.20
Long Term Debt And Capital Lease Obligation
1.58
-36.79%
2.51
-26.42%
3.41
-18.94%
4.20
Long Term Capital Lease Obligation
1.58
-36.79%
2.51
-26.42%
3.41
-18.94%
4.20
Non Current Deferred Liabilities
—
—
—
0.00
Non Current Deferred Revenue
—
—
—
—
Stockholders Equity
82.39
+3.47%
79.63
-44.97%
144.71
-17.85%
176.16
Common Stock Equity
82.39
+3.47%
79.63
-44.97%
144.71
-17.85%
176.16
Capital Stock
0.01
+40.00%
0.01
+0.00%
0.01
+0.00%
0.01
Common Stock
0.01
+40.00%
0.01
+0.00%
0.01
+0.00%
0.01
Share Issued
63.28
+32.62%
47.71
+0.96%
47.26
+11.49%
42.39
Ordinary Shares Number
63.28
+32.62%
47.71
+0.96%
47.26
+11.49%
42.39
Additional Paid In Capital
512.91
+11.18%
461.34
+2.29%
451.01
+13.88%
396.04
Retained Earnings
-430.53
-12.79%
-381.72
-24.62%
-306.31
-39.86%
-219.01
Gains Losses Not Affecting Retained Earnings
0.01
+200.00%
0.00
-50.00%
0.00
+100.46%
-0.88
Other Equity Adjustments
0.01
+200.00%
0.00
-50.00%
0.00
+100.46%
-0.88
Total Equity Gross Minority Interest
82.39
+3.47%
79.63
-44.97%
144.71
-17.85%
176.16
Total Capitalization
82.39
+3.47%
79.63
-44.97%
144.71
-17.85%
176.16
Working Capital
75.42
+7.29%
70.30
-46.65%
131.77
-17.45%
159.62
Invested Capital
82.39
+3.47%
79.63
-44.97%
144.71
-17.85%
176.16
Total Debt
2.42
-28.92%
3.41
-18.94%
4.20
-14.30%
4.90
Capital Lease Obligations
2.42
-28.92%
3.41
-18.94%
4.20
-14.30%
4.90
Net Tangible Assets
82.39
+3.47%
79.63
-44.97%
144.71
-17.85%
176.16
Tangible Book Value
82.39
+3.47%
79.63
-44.97%
144.71
-17.85%
176.16
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-39.88
+34.10%
-60.52
+25.50%
-81.23
+14.04%
-94.50
Cash Flow From Continuing Operating Activities
-39.88
+34.10%
-60.52
+25.50%
-81.23
+14.04%
-94.50
Net Income From Continuing Operations
-48.81
+35.28%
-75.41
+13.62%
-87.30
+14.37%
-101.94
Depreciation Amortization Depletion
3.69
-3.68%
3.83
-5.27%
4.04
+31.53%
3.07
Depreciation
3.69
-3.68%
3.83
-5.27%
4.04
+31.53%
3.07
Depreciation And Amortization
3.69
-3.68%
3.83
-5.27%
4.04
+31.53%
3.07
Other Non Cash Items
-0.60
-239.95%
0.43
+17.58%
0.36
+20.53%
0.30
Stock Based Compensation
7.00
-26.72%
9.55
+37.57%
6.94
+7.38%
6.46
Operating Gains Losses
0.08
-63.51%
0.22
-26.73%
0.30
-56.96%
0.70
Change In Working Capital
-0.79
-125.98%
3.02
+173.77%
-4.09
+8.27%
-4.46
Change In Prepaid Assets
1.82
-71.45%
6.37
-39.12%
10.46
+372.20%
-3.84
Change In Payables And Accrued Expense
-1.76
+30.60%
-2.54
+81.78%
-13.92
-10567.67%
0.13
Change In Accrued Expense
-1.44
+57.19%
-3.37
+59.39%
-8.29
-378.76%
2.98
Change In Payable
-0.32
-138.22%
0.83
+114.78%
-5.63
-98.06%
-2.84
Change In Account Payable
-0.32
-138.22%
0.83
+114.78%
-5.63
-98.06%
-2.84
Change In Other Working Capital
—
—
0.34
—
Change In Other Current Assets
0.08
-12.22%
0.09
-45.45%
0.17
+411.32%
-0.05
Change In Other Current Liabilities
-0.92
-2.44%
-0.90
-13.07%
-0.80
-13.39%
-0.70
Investing Cash Flow
-7.89
+7.33%
-8.51
-107.68%
110.86
+124.24%
49.44
Cash Flow From Continuing Investing Activities
-7.89
+7.33%
-8.51
-107.68%
110.86
+124.24%
49.44
Net PPE Purchase And Sale
-0.07
-20.34%
-0.06
+85.50%
-0.41
+96.46%
-11.51
Purchase Of PPE
-0.07
-20.34%
-0.06
+85.50%
-0.41
+96.50%
-11.61
Sale Of PPE
—
—
0.00
-100.00%
0.10
Capital Expenditure
-0.07
-20.34%
-0.06
+85.50%
-0.41
+96.50%
-11.61
Net Investment Purchase And Sale
-7.82
+7.52%
-8.45
-107.60%
111.27
+82.56%
60.95
Purchase Of Investment
-43.42
+53.59%
-93.55
-17.33%
-79.73
+39.77%
-132.38
Sale Of Investment
35.60
-58.17%
85.10
-55.44%
191.00
-1.20%
193.32
Financing Cash Flow
44.57
+5563.79%
0.79
-98.38%
48.62
+28330.41%
0.17
Cash Flow From Continuing Financing Activities
44.57
+5563.79%
0.79
-98.38%
48.62
+28330.41%
0.17
Net Common Stock Issuance
44.48
+261717.65%
-0.02
-100.04%
48.17
0.00
Common Stock Payments
—
-0.02
—
—
Repurchase Of Capital Stock
—
-0.02
—
—
Proceeds From Stock Option Exercised
0.16
-86.93%
1.25
+151.50%
0.50
+191.81%
0.17
Net Other Financing Charges
-0.07
+85.59%
-0.45
-750.94%
-0.05
—
Changes In Cash
-3.19
+95.32%
-68.24
-187.21%
78.25
+274.31%
-44.89
Beginning Cash Position
57.39
-54.32%
125.63
+165.15%
47.38
-48.65%
92.27
End Cash Position
54.19
-5.57%
57.39
-54.32%
125.63
+165.15%
47.38
Free Cash Flow
-39.95
+34.04%
-60.57
+25.80%
-81.64
+23.07%
-106.11
Amortization Of Securities
-0.45
+78.94%
-2.15
-45.04%
-1.48
-208.25%
1.37
Common Stock Issuance
44.48
—
48.17
0.00
Issuance Of Capital Stock
44.48
—
48.17
0.00
Net Preferred Stock Issuance
—
—
—
—
Preferred Stock Issuance
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category